Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Novo Nordisk inks $812M Deep Apple deal to pursue obesity target
The Danish drugmaker has partnered with Deep Apple Therapeutics to access small molecules against a non-incretin GPCR target.
Nick Paul Taylor
Jun 11, 2025 7:00am
Metsera posts amylin data, eyes monthly GLP-1 combo
Jun 9, 2025 7:00am
Eli Lilly taps Camurus' tech to advance long-acting obesity meds
Jun 3, 2025 5:04pm
BioAge inks option agreement for Chinese biotech's obesity asset
Jun 3, 2025 2:06pm
Fierce Pharma
Novo's longtime CEO Lars Fruergaard Jørgensen to step down
May 16, 2025 9:41am
Novo inks $2.2B deal for Septerna's preclinical obesity programs
May 14, 2025 7:00am
